Development of a High-Content Stem Cell Focused Drug Screening Platform for Schistosoma mansoni Using Developmentally Advanced Liver Schistosomula - Functional Insights and New Protein Target Leads

Clicks: 14
ID: 323170
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #226 of 439 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 439 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Globally, more than a quarter of a billion people are infected with Schistosoma blood parasites that cause the debilitating disease human schistosomiasis. To assist drug discovery, we developed a novel high content drug screening platform that exploits the extraordinary stem cell biology of the developing parasite. METHOD: Employing non-synchronous in vitro-grown liver stage schistosomula, fluorescence-based staining, confocal laser scanning microscopy, and segmentation of multi-parasite images, the platform was designed to enable high-content quantitative analysis of dividing somatic neoblasts within the parasite to define phenotype. RESULTS: To establish, refine, and test the approach we analysed stem cell proliferation in liver stage schistosomula and validated the impact of EC-144, a compound that supresses Schistosoma neoblast proliferation. Primary drug screening was then done using a stem cell focused library containing 280 compounds, 45 of which attenuated stem cell proliferation by at least 75%. Sixteen 'hit' compounds were prioritised for further testing/confirmation, with testing done in both simple and complex media. Six compounds were finally selected for further investigation, all of which killed or constrained the development of schistosomula and abolished both somatic and germinal stem cell proliferation in adult male and female worms. CONCLUSIONS: In addition to identifying a panel of new anti-schistosomal compounds with associated predicted targets, the findings provide mechanistic insights into the somatic stem cell biology of schistosomes. Further application of this platform, which offers a new approach to assessing compound susceptibility on schistosomula, should accelerate lead compound discovery to help fight human schistosomiasis.
Reference Key
openalex_W7171924816 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sewwandi Perera, Athina‐Myrto Chioni, Anthony J. Walker
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag392
URL
https://doi.org/10.1093/infdis/jiag392
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.